The ELR+CXCL chemokines and their receptors CXCR1/CXCR2: A signaling axis and new target for the treatment of renal cell carcinoma

Sandy Giuliano; Mélanie Guyot; Renaud Grépin; Gilles Pagès

doi:10.4161/onci.28399

The ELR⁺CXCL chemokines and their receptors CXCR1/CXCR2: A signaling axis and new target for the treatment of renal cell carcinoma

Oncoimmunology. 2014 Apr 9:3:e28399. doi: 10.4161/onci.28399. eCollection 2014.

Authors

Sandy Giuliano¹, Mélanie Guyot¹, Renaud Grépin², Gilles Pagès¹

Affiliations

¹ University of Nice Sophia Antipolis; UMR CNRS 7284/U INSERM 1081; Nice, France.
² Centre Scientifique de Monaco; Monaco.

Abstract

The long-term efficacy of anti-angiogenesis drugs targeting vascular endothelial growth factor (VEGF) and VEGF receptors in the treatment of renal cell carcinoma (RCC) has been lacking. We have shown that the ELR⁺CXCL cytokines and their (C-X-C) chemokine receptors, namely CXCR1 and CXCR2, stimulate cancer cell proliferation, tumor inflammation, and angiogenesis. Hence, this essential molecular nexus regulating cancer growth represents a key therapeutic target.

Keywords: CXCL7; CXCR1; CXCR2; ELR+CXCL; angiogenesis; inflammation; renal cell carcinoma.

Publication types

Research Support, Non-U.S. Gov't